DNA methylation data analysis and its application to cancer research

Epigenomics

Volumn 5, Issue 3, 2013, Pages 301-316

  Ma, Xiaotu ^a   Wang, Yi Wei ^b   Zhang, Michael Q ^a,c   Gazdar, Adi F ^b,d  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c TSINGHUA UNIVERSITY   (China)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

cancer testis antigen; computational biology; data analysis; DNA methylation; Encyclopedia of DNA Elements Consortium; gene expression; imprinted gene; Infinium HumanMethylation450 BeadChip ; NIH Roadmap Epigenomics Mapping Consortium; The Cancer Genome Atlas

Indexed keywords

CANCER TESTIS ANTIGEN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; GRIK2 PROTEIN; LHX2 PROTEIN; MAGEA1 PROTEIN; PROTEIN; RNA H19; SEPTIN; TSPYL5 PROTEIN; UNCLASSIFIED DRUG;

5' UNTRANSLATED REGION; BASE PAIRING; BIOINFORMATICS; CANCER CLASSIFICATION; CANCER GENETICS; CANCER RESEARCH; CLEAR CELL CARCINOMA; COLON CROHN DISEASE; CPG ISLAND; DATA MINING; DNA BASE COMPOSITION; DNA METHYLATION; DNA PROBE; DNA SEQUENCE; EPIGENETICS; EXON; GENE DOSAGE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE REPRESSION; GENE SEQUENCE; GENETIC VARIABILITY; GENOME; GENOME IMPRINTING; HISTONE MODIFICATION; HUMAN; IMMUNOPRECIPITATION; KIDNEY CARCINOMA; LUNG ADENOCARCINOMA; LUNG SQUAMOUS CELL CARCINOMA; METHYLOME; MOLECULAR BIOLOGY; NANOCHIP; NEXT GENERATION SEQUENCING; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTION REGULATION; ULCERATIVE COLITIS; X CHROMOSOME;

COMPUTATIONAL BIOLOGY; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DATA MINING; DATABASES, GENETIC; DNA METHYLATION; GENE EXPRESSION; GENOME, HUMAN; GENOMIC IMPRINTING; HUMANS; NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS;

EID: 84879092628     PISSN: 17501911     EISSN: 1750192X     Source Type: Journal    
DOI: 10.2217/epi.13.26     Document Type: Review

References (56)

1. Schena M, Shalon D, Davis RW, Brown PO. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 270(5235), 467-470 (1995).
2. Ren B, Robert F, Wyrick JJ et al. Genome-wide location and function of DNA binding proteins. Science 290(5500), 2306-2309 (2000).
3. Wang DG, Fan JB, Siao CJ et al. Large-scale identification, mapping, and genotyping of single-nucleotide polymorphisms in the human genome. Science 280(5366), 1077-1082 (1998).
4. Bibikova M, Barnes B, Tsan C et al. High density DNA methylation array with single CpG site resolution. Genomics 98(4), 288-295 (2011).
5. Laird PW. Principles and challenges of genomewide DNA methylation analysis. Nat. Rev. Genet. 11(3), 191-203 (2010).
6. Lister R, Pelizzola M, Dowen RH et al. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature 462(7271), 315-322 (2009).
7. Fouse SD, Nagarajan RO, Costello JF. Genome-scale DNA methylation analysis. Epigenomics 2(1), 105-117 (2010).
8. Li M, Wu H, Luo Z et al. An atlas of DNA methylomes in porcine adipose and muscle tissues. Nat. Commun. 3, 850 (2012).
9. Jones PA. Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat. Rev. Genet. 13(7), 484-492 (2012).
10. Doi A, Park IH, Wen B et al. Differential methylation of tissue-and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts. Nat. Genet. 41(12), 1350-1353 (2009).
11. Sandoval J, Heyn H, Moran S et al. Validation of a DNA methylation microarray for 450,000 CpG sites in the human genome. Epigenetics 6(6), 692-702 (2011).
12. Baylin SB. DNA methylation and gene silencing in cancer. Nat. Clin. Pract. Oncol. 2(Suppl. 1), S4-S11 (2005).
13. Jjingo D, Conley AB, Yi SV, Lunyak VV, Jordan IK. On the presence and role of human gene-body DNA methylation. Oncotarget 3(4), 462-474 (2012).
14. Feinberg AP. Genome-scale approaches to the epigenetics of common human disease. Virchows Arch. 456(1), 13-21 (2010).
15. Feinberg AP. Epigenomics reveals a functional genome anatomy and a new approach to common disease. Nat. Biotechnol. 28(10), 1049-1052 (2010).
16. Eckhardt F, Lewin J, Cortese R et al. DNA methylation profiling of human chromosomes 6, 20 and 22. Nat. Genet. 38(12), 1378-1385 (2006).
17. The International HapMap Consortium. A haplotype map of the human genome. Nature 437(7063), 1299-1320 (2005).
18. Dunham I, Kundaje A, Aldred SF et al. An integrated encyclopedia of DNA elements in the human genome. Nature 489(7414), 57-74 (2012).
19. Meissner A, Mikkelsen TS, Gu H et al. Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature 454(7205), 766-770 (2008).
20. Aryee MJ, Wu Z, Ladd-Acosta C et al. Accurate genome-scale percentage DNA methylation estimates from microarray data. Biostatistics 12(2), 197-210 (2011).
21. Du P, Zhang X, Huang CC et al. Comparison of beta-value and M-value methods for quantifying methylation levels by microarray analysis. BMC Bioinformatics 11, 587 (2010).
22. Maksimovic J, Gordon L, Oshlack A. SWAN: subset-quantile within array normalization for Illumina Infinium HumanMethylation450 BeadChips. Genome Biol. 13(6), R44 (2012).
23. Zhang X, Mu W, Zhang W. On the analysis of the Illumina 450k array data: probes ambiguously mapped to the human genome. Front Genet. 3, 73 (2012).
24. Mancini D, Singh S, Ainsworth P, Rodenhiser D. Constitutively methylated CpG dinucleotides as mutation hot spots in the retinoblastoma gene (RB1). Am. J. Hum. Genet. 61(1), 80-87 (1997).
25. Choe SE, Boutros M, Michelson AM, Church GM, Halfon MS. Preferred analysis methods for Affymetrix GeneChips revealed by a wholly defined control dataset. Genome Biol. 6(2), R16 (2005).
26. Wang D, Yan L, Hu Q et al. IMA. An R package for high-throughput analysis of Illumina's 450K Infinium methylation data. Bioinformatics 28(5), 729-730 (2012).
27. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Series B Stat. Methodol. 289-300 (1995).
28. Selamat SA, Chung BS, Girard L et al. Genome-scale analysis of DNA methylation in lung adenocarcinoma and integration with mRNA expression. Genome Res. 22(7), 1197-1211 (2012).
29. Jaffe AE, Feinberg AP, Irizarry RA, Leek JT. Significance analysis and statistical dissection of variably methylated regions. Biostatistics 13(1), 166-178 (2012).
30. Matys V, Fricke E, Geffers R et al. TRANSFAC: transcriptional regulation, from patterns to profiles. Nucleic Acids Res. 31(1), 374-378 (2003).
31. Newburger DE, Bulyk ML. UniPROBE: an online database of protein binding microarray data on protein-DNA interactions. Nucleic Acids Res. 37(Database issue), D77-D82 (2009).
32. Bryne JC, Valen E, Tang MH et al. JASPAR, the open access database of transcription factor-binding profiles: new content and tools in the 2008 update. Nucleic Acids Res. 36(Database issue), D102-D106 (2008).
33. Ioshikhes IP, Zhang MQ. Large-scale human promoter mapping using CpG islands. Nat. Genet. 26(1), 61-63 (2000).
34. Landry JR, Mager DL, Wilhelm BT. Complex controls: the role of alternative promoters in mammalian genomes. Trends Genet. 19(11), 640-648 (2003).
35. Davuluri RV, Grosse I, Zhang MQ. Computational identification of promoters and first exons in the human genome. Nat. Genet. 29(4), 412-417 (2001).
36. Taylor SM, Jones PA. Multiple new phenotypes induced in 10T1/2 and 3T3 cells treated with 5-azacytidine. Cell 17(4), 771-779 (1979).
37. Baylin SB. The cancer epigenome: its origins, contributions to tumorigenesis, and translational implications. Proc. Am. Thorac. Soc. 9(2), 64-65 (2012).
38. Merlo A, Herman JG, Mao L et al. 5́ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat. Med. 1(7), 686-692 (1995).
39. Herman JG, Merlo A, Mao L et al. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res. 55(20), 4525-4530 (1995).
40. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res. 61(8), 3225-3229 (2001).
41. Krtolica K, Krajnovic M, Usaj-Knezevic S, Babic D, Jovanovic D, Dimitrijevic B. Comethylation of p16 and MGMT genes in colorectal carcinoma: correlation with clinicopathological features and prognostic value. World J. Gastroenterol. 13(8), 1187-1194 (2007).
42. Zang JJ, Xie F, Xu JF et al. p16 gene hypermethylation and hepatocellular carcinoma: a systematic review and meta-analysis. World J. Gastroenterol. 17(25), 3043-3048 (2011).
43. Salvesen HB, Das S, Akslen LA. Loss of nuclear p16 protein expression is not associated with promoter methylation but defines a subgroup of aggressive endometrial carcinomas with poor prognosis. Clin. Cancer Res. 6(1), 153-159 (2000).
44. Reik W, Walter J. Genomic imprinting: parental influence on the genome. Nat. Rev. Genet. 2(1), 21-32 (2001).
45. Rainier S, Johnson LA, Dobry CJ, Ping AJ, Grundy PE, Feinberg AP. Relaxation of imprinted genes in human cancer. Nature 362(6422), 747-749 (1993).
46. Hansen KD, Timp W, Bravo HC et al. Increased methylation variation in epigenetic domains across cancer types. Nat. Genet. 43(8), 768-775 (2011).
47. Harris RA, Nagy-Szakal D, Pedersen N et al. Genome-wide peripheral blood leukocyte DNA methylation microarrays identified a single association with inflammatory bowel diseases. Inflamm. Bowel Dis. 18(12), 2334-2341 (2012).
48. Heyn H, Li N, Ferreira HJ et al. Distinct DNA methylomes of newborns and centenarians. Proc. Natl Acad. Sci. USA 109(26), 10522-10527 (2012).
49. Horvath S, Zhang Y, Langfelder P et al. Aging effects on DNA methylation modules in human brain and blood tissue. Genome Biol. 13(10), R97 (2012).
50. Nazor KL, Altun G, Lynch C et al. Recurrent variations in DNA methylation in human pluripotent stem cells and their differentiated derivatives. Cell Stem Cell 10(5), 620-634 (2012).
51. Zendman AJ, Ruiter DJ, van Muijen GN. Cancer/testis-associated genes: identification, expression profile, and putative function. J. Cell. Physiol. 194(3), 272-288 (2003).
52. Scanlan MJ, Simpson AJ, Old LJ. The cancer/testis genes: review, standardization, and commentary. Cancer Immun. 4, 1 (2004).
53. Kim KH, Choi JS, Kim IJ, Ku JL, Park JG. Promoter hypomethylation and reactivation of MAGE-A1 and MAGE-A3 genes in colorectal cancer cell lines and cancer tissues. World J. Gastroenterol. 12(35), 5651-5657 (2006).
54. Suzuki H, Maruyama R, Yamamoto E, Kai M. DNA methylation and microRNA dysregulation in cancer. Mol. Oncol. 6(6), 567-578 (2012).
55. Greenfield A, Carrel L, Pennisi D et al. The UTX gene escapes X inactivation in mice and humans. Hum. Mol. Genet. 7(4), 737-742 (1998).
56. Turcan S, Rohle D, Goenka A et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 483(7390), 479-483 (2012).